<DOC>
	<DOCNO>NCT00758602</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety CellCept , combine low standard dose tacrolimus plus corticosteroid , patient kidney transplant . Patients randomize one 2 group receive either 1 ) CellCept 2.0g/day po bid + tacrolimus 10-12ng/mL followed maintenance dose 8-10ng/mL + corticosteroid 2 ) CellCept 2.0g/day po bid + tacrolimus 8-10ng/mL first 2 months,3-7ng/mL month 3 follow maintenance dose 3-5ng/mL + corticosteroid . The anticipated time study treatment 1 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study CellCept ( Mycophenolate Mofetil ) Combined With Tacrolimus Corticosteroids Kidney Transplant Patients .</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>adult patient , &lt; =75 year age ; single organ recipient renal allograft ; negative pregnancy test woman childbearing potential ; reliable contraception must use start drug therapy , 6 week last dose study medication . severe gastrointestinal disease may influence absorption oral drug therapy ; severe infection , HIV active hepatitis ; active gastric ulcer ; malignancy cure skin cancer ; severe anemia , leucopenia thrombocytopenia .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>